BioNotebook: Versant raises $305m venture fund; plus deal notes from Pfizer/iTeos, Juno/Opus, CHI/BayBio
This article was originally published in Scrip
Versant Ventures closed its fifth health care-focused venture capital fund with a $305m total that exceeded the San Francisco-based firm's $250m goal.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.